AB Science Updates on Masitinib Platform Progress

On January 29, 2025, AB Science presented updates on its masitinib platform. The emphasis was on its various applications in treating Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Alzheimer's Disease. A new confirmatory study for ALS, designed with input from the FDA and EMA, is underway. Data suggests potential survival benefits for ALS patients, with some surviving over a decade on masitinib treatment.

For Progressive MS, masitinib’s mechanism has shown promise in targeting microglia and mast cell activity. The drug's efficacy appears competitive against other emerging treatments. Meanwhile, in Alzheimer's, masitinib stands out as having positive results in moderate cases, with potential to combine with other treatments for mild stages.

The company highlights the substantial unmet medical need in these areas, noting significant market opportunities with masitinib. Intellectual property is secured into the 2040s, enhancing the drug's strategic value. Importantly, AB Science is negotiating a stand-still on a 3.7M€ debt to focus resources on further research and development efforts.